Circulating tumor DNA (ctDNA) analyses as a predictive marker for cancer treatment in solid tumors
Not Applicable
Recruiting
- Conditions
- Neoplasms
- Registration Number
- KCT0008188
- Lead Sponsor
- Chonnam National University Hospital Hwasun Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Male and female participants >=18 years of age inclusive, at the time of signing the informed consent
Histologically confirmed metastatic solid cancer
Participants with accessible tumor will undergo a pre-treatment
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 after operation, radiotherapy or chemotherapy
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Agreement to donate blood sample (20ml) during the study period
Ability to comply with the study protocol in the investigator's judgement
Exclusion Criteria
Histologically who are not confirmed with solid cancer
Amount of sample that can not be analyzed
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method circulating tumor DNA
- Secondary Outcome Measures
Name Time Method Progression free survival, Overall survival